A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma
← catalyst calendarNCT05456256 · readout ≤ 134 d
Sponsored by Lantern Pharma Inc. (industry) · LTRN — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
90estimated
Sites
16
Countries
Japan, Taiwan, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-03-01 | actual | When the study began enrolling |
| Primary completion | Dec 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jun 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2022-07-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Adenocarcinoma of Lung
- Carcinoma, Non-Small-Cell Lung
Interventions
- Drug: LP-300 — also filed as Tavocept, BNP7787, Dimesna
- Drug: Pemetrexed — also filed as Alimta, Pemfexy
- Drug: Carboplatin — also filed as Paraplatin
Primary outcomes
what the primary-completion date above is the date OFProgression-free survival (PFS)
measured Through study completion, an average of 2 years
Overall survival (OS)
measured Through study completion, an average of 2 years
Permalink · LTRN's whole pipeline · Catalyst calendar · Every registered study · What changed